Annandale Capital’s Cullinan Oncology CGEM Stock Holding History

Annandale Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,000	Closed	-$122K	–	138
2023 Q4	$122K	Hold	12,000	–	–	0.02%	136
2023 Q3	$109K	Buy	12,000 +2,000	+20%	+$20.8K	0.03%	126
2023 Q2	$108K	Hold	10,000	–	–	0.03%	128
2023 Q1	$102K	Hold	10,000	–	–	0.03%	124
2022 Q4	$106K	Hold	10,000	–	–	0.03%	125
2022 Q3	$128K	Buy	+10,000	New	+$135K	0.05%	123

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Annandale Capital's CGEM Position: Q1 2024 in Review

Annandale Capital sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 12,000 shares — an estimated $122K sold.

Annandale Capital first reported a position in CGEM in Q3 2022 and held it in 6 quarters. The position peaked at $128K in Q3 2022. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

Annandale Capital reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
Annandale Capital sold 12,000 Cullinan Oncology shares in Q1 2024, an estimated $122K.
Annandale Capital first reported a position in Cullinan Oncology in Q3 2022 and held it in 6 quarters.
Annandale Capital's Cullinan Oncology position peaked at $128K in Q3 2022.
113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Annandale Capital's 13F filing for Q1 2024, filed 15 May 2024.